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Background
Familial amyloid polyneuropathy (FAP) is a severe her-
editary disease, due to production by the liver of a
genetic variant transthyretin (TTR) resulting in tissue
amyloid deposits. Cardiac involvement is of major prog-
nostic value. Diphosphonate scintigraphy has been pro-
posed as a diagnostic tool for TTR-related cardiac
amyloidosis, but there is no consensus on the optimal
radiopharmaceutical. Consequently, we compared the
cardiac uptake of two 99mTc-labelled tracers: dipho-
sphono-propanedicarboxylic acid (DPD) and hydroxy-
methylene diphosphonate (HMDP) in patients with
TTR-FAP.
Methods
122 consecutive patients with TTR-FAP were prospec-
tively included and received randomly DPD or HMDP.
Acquisitions (whole-body (WB) and chest SPECT)
were performed 3 hours after intravenous injection of
the tracer. Quantification of myocardial uptake on WB
acquisitions was performed by use of the ratio between
the geometric mean of either total or average counts of
a region of interest (ROI) drawn over the heart area
and the WB total or average counts (H/WBtotal or
H/WBaverage). Quantification on SPECT acquisitions
was performed by the ratio between 3D isocount
volume of interest generated over the myocardium and
a standard volume in the right lung (H/L). Quantifica-
tion of soft tissues uptake was performed by use of
ratio between average counts of a ROI drawn over the
lumbar spine and a ROI drawn over soft tissues of the
lower limb (B/ST) on the WB acquisition.
Results
The DPD and HMDP groups of patients had similar age
(62±15 vs. 59±14 years respectively; p=0.3), sex (males:
67% vs. 58% respectively; p=0.4), TTR mutation (Val30-
Met: 70% vs. 80% respectively; p=0.3) and activity of the
tracer (DPD: 713±86 MBq vs. HMDP: 709±124 MBq;
p=0.9). Quantitative parameters derived from whole
body acquisition were significantly greater with DPD
compared to HMDP (H/WBtotal: 3.8±2.7 vs. 2.4±2.1
respectively; p=0.002 and H/WBaverage: 5.2±2.2 vs.
4.3±1.3 respectively; p=0.01) as well as H/L derived
from SPECT acquisition (3.9±3.7 vs. 2.0±1.9 respectively;
p=0.001). The uptake by soft tissues was also greater in
the DPD compared to HMDP group (B/ST: 3.6±2.0 vs.
5.7±2.9 respectively; p<0.0001).
Conclusion
The present study shows that in patients with TTR FAP,
the uptake of DPD in heart and other soft tissues is
superior to that of HMDP. This suggests that DPD
should be prioritized for initial assessment of patients
suspected of cardiac involvement of TTR-related amy-
loidosis. Further study is required to assess whether this
difference impacts the diagnostic performance and
whether DPD is more accurate for the assessment of
therapy response.
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